EPA:SAN - Sanofi Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started Previous Close€66.23Today's Range€65.87 - €66.5852-Week Range€63.09 - €92.97Volume6.89 million shsAverage Volume3.05 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartHeadlinesOptions Chain Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis. The company also provides Jevtana, a taxane derivative for prostate cancer; Taxotere, a taxoid for cancers; Eloxatin, an agent for colorectal cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil, a hematopoietic stem cell mobilizer; and Zaltrap, a protein for metastatic colorectal cancer. In addition, it offers Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl, an oral sulfonylurea; Lyxumia/Adlyxin, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug for atrial fibrillation. Further, the company provides Plavix, an anti-platelet agent for atherothrombotic conditions; Lovenox, a heparin for the prophylaxis and venous thromboembolism and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela oral phosphate binders for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; and Allegra for seasonal allergic rhinitis and uncomplicated hives. Additionally, it offers consumer health care products and generic medicines; and pediatric, influenza, adult and adolescent booster, meningitis, and travel and endemic vaccines. Sanofi has strategic alliance with Sensile Medical Ltd.; collaboration with Evotec AG; and partnership with REVOLUTION Medicines, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France. Receive SAN News and Ratings via Email Sign-up to receive the latest news and ratings for SAN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange EPA Industry Drug Manufacturers - Major Sub-IndustryN/A SectorMedical Current SymbolEPA:SAN Previous Symbol CUSIPN/A Weben.sanofi.com Phone+33-1-53774000 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees106,566 Outstanding SharesN/AMarket Cap$0.00 OptionableOptionable Sanofi (EPA:SAN) Frequently Asked Questions What is Sanofi's stock symbol? Sanofi trades on the EPA under the ticker symbol "SAN." What price target have analysts set for SAN? 18 brokerages have issued 1-year price targets for Sanofi's stock. Their forecasts range from €72.00 to €95.00. On average, they expect Sanofi's stock price to reach €83.72 in the next twelve months. View Analyst Price Targets for Sanofi. What is the consensus analysts' recommendation for Sanofi? 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sanofi in the last year. There are currently 9 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sanofi. Has Sanofi been receiving favorable news coverage? News articles about SAN stock have trended negative recently, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Sanofi earned a media sentiment score of -2.4 on InfoTrie's scale. They also gave media stories about the company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the stock's share price in the next several days. Who are some of Sanofi's key competitors? Some companies that are related to Sanofi include Allergy Therapeutics (AGY), Antisense Therapeutics (ANP), AstraZeneca (AZN), Avivagen (VIV), Bayer (BAYN), Bayer (BAYN), BEXIMCO PHARMAC/S GDR REGS (BXP), Cathay International (CTI), China Pharma (CPHI), Dechra Pharmaceuticals (DPH), Eco Animal Health Group (EAH), Futura Medical (FUM), GlaxoSmithKline (GSK), Hutchison China MediTech (HCM) and Mayne Pharma Group (MYX). Who are Sanofi's key executives? Sanofi's management team includes the folowing people: Mr. Olivier Brandicourt, CEO & Director (Age 62)Mr. Jean-Baptiste Chasseloup de Chatillon, Exec. VP & CFO (Age 53)Mr. Laurent Gilhodes, Principal Accounting Officer and VP of Corp. AccountingMr. Bruno Ménard, Chief Information officerMr. George Grofik, Head of Investor Relations What is Sanofi's official website? The official website for Sanofi is http://en.sanofi.com. How can I contact Sanofi? Sanofi's mailing address is 54 rue la Boetie, PARIS, 75008, France. The company can be reached via phone at +33-1-53774000. MarketBeat Community Rating for Sanofi (EPA SAN)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 490 (Vote Outperform)Underperform Votes: 585 (Vote Underperform)Total Votes: 1,075MarketBeat's community ratings are surveys of what our community members think about Sanofi and other stocks. Vote "Outperform" if you believe SAN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SAN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/18/2018 by MarketBeat.com StaffFeatured Article: What is an investor looking for in an SEC filing?